FMI Immune Checkpoint Inhibitors Market Value Share, A | Page 4

Immune Checkpoint Inhibitors Market
Immune Checkpoint Inhibitors Market Analysis and Value Forecast Snapshot by End-use Industry 2017-
2027
Cancer is the leading cause of death worldwide and hence offers a lot of unmet research areas yet to be
targeted. The field of oncology is wide comprising a varied type of application area. The focus of
researchers is gradually shifting towards the immunotherapies. The immunotherapy makes the use of
body’s own components to fight cancer. Immune checkpoints are molecules that stimulate or inhibit the
immune cells. Yervoy was the first drug launched in the immune checkpoint inhibitors domain. This anit-
CTLA-4 drug was followed by many other drugs such as Keytruda and Opdivo. Besides these molecules
there are several others under clinical development. There is an ongoing competition between the
immune checkpoint inhibitors market contributors to emerge as a leader.
Immune Checkpoint Inhibitors Market: Drivers and Restraints
The immune checkpoint inhibitors market is driven by the number of research developments undertaken
by industry contributors as well as academic institutes. The immune checkpoint inhibitors market is
experiencing a lot of collaborations wherein companies are combining their core competencies to fasten
their research programs. For instance, Merck known as MSD outside the U.S. and Canada along with
Dynavax Technologies Corporation are investigating the potential synergistic effects by combining
Dynavax's SD-101 with two of Merck’s immunotherapies Keytruda and MK-1966.
Request Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-3326
©2015 Future Market Insights, All Rights Reserved
4